<DOC>
	<DOC>NCT00414466</DOC>
	<brief_summary>The purpose of this study is to determine the safety and minimum effective dose of intraspinal gabapentin when delivered through an implanted drug infusion system.</brief_summary>
	<brief_title>A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain</brief_title>
	<detailed_description />
	<mesh_term>Pain, Intractable</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Chronic pain below the neck present for a minimum of one year. Diagnosis of at least one of the following: back pain with or without leg pain, postherpetic neuralgia, complex regional pain syndrome (CRPS) 1 or 2, diabetic neuropathy, or a general neuropathic condition; medically stable and able to undergo surgery for implantation of the drug infusion system.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>